scispace - formally typeset
M

Maki Goto

Researcher at Hokkaido University

Publications -  38
Citations -  1488

Maki Goto is an academic researcher from Hokkaido University. The author has contributed to research in topics: Mutation & Keratinocyte. The author has an hindex of 18, co-authored 33 publications receiving 1379 citations.

Papers
More filters
Journal ArticleDOI

Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer

TL;DR: It is concluded that ABCA 12 works as an epidermal keratinocyte lipid transporter and that defective ABCA12 results in a loss of the skin lipid barrier, leading to HI.
Journal ArticleDOI

Humanization of autoantigen

TL;DR: It is shown that human autoimmune disease can be reproduced using genetically engineered model mice and injected human BP autoantibody into Col17-knockout mice rescued by the human ortholog, resulting in BP-like skin lesions and a human disease phenotype.
Journal ArticleDOI

Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.

TL;DR: It is concluded that skipping of targeted exons using mutation-specific AON may show potential for future gene therapy for DEB patients, as it induced effective skipping of normal exon 70 containing 16 amino acids.
Journal ArticleDOI

Fibroblasts Show More Potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis Bullosa

TL;DR: Results suggest that fibroblasts may be a better gene therapy target of DEB treatment than keratinocytes, and which gene-transferred cells can most efficiently express collagen VII in the skin.
Journal ArticleDOI

Epidermolysis Bullosa Simplex Associated with Pyloric Atresia Is a Novel Clinical Subtype Caused by Mutations in the Plectin Gene (PLEC1)

TL;DR: Results indicate that PLEC1 is a possible causative gene in this clinical subtype, EBS associated with PA, and in terms of clinical prognosis, this novel subtype is the lethal variant in the EBS category.